{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039769","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.592447+00:00","generated_at":"2026-06-12T01:06:36.936502+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement","bullets":["Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.","Net loss $15.6M for Q2 2023 vs $14.4M in Q2 2022; R&D expense flat at $10.8M.","ENLIGHTEN I Phase 3 enrollment completion expected in weeks; data 1H 2024.","BEACON Phase 2 topline results for LYR-220 now expected September 2023.","Private placement closed May 31, 2023 yielded net proceeds of $46.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039769","json":"https://secwatch.observer/filing/0000950170-23-039769.json","markdown":"https://secwatch.observer/filing/0000950170-23-039769.md","text":"https://secwatch.observer/filing/0000950170-23-039769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/0000950170-23-039769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/lyra-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:06:36.936502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"890fe576def851807c674be98d17d19c5f30bf91","claim":"Lyra Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $15.6 million.","evidence_excerpt":"Net loss for the quarter ended June 30, 2023 was $15.6 million compared to $14.4 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/0000950170-23-039769-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$15.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}